Editas Medicine shares surge 14.11% premarket after Baird raises price target to $6 from $4.

Editas Medicine surged 14.11% in premarket trading following a price target increase from Baird, which raised its estimate to $6 from $4. This upgrade, announced 3 hours prior, signaled improved analyst sentiment amid ongoing developments in the company’s gene-editing pipeline. While other news, such as institutional share purchases and preclinical data updates, occurred earlier in 2025, the immediate catalyst aligns with Baird’s revised outlook, reinforcing investor confidence ahead of the stock’s premarket rally.